AtaiBeckley Inc

ATAI

Healthcare|Biotechnology|USA

$5.17

-0.16 (-3.00%)

Tangible Book

$0.54

About

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Stock Price

+89.4%(1Y)

Pipeline Summary

0 total trials

Phase 1

Phase 2

Phase 3

Phase 4

BioScore

3.5/10

Cautious

Ownership

Recent Insider Trades

HERSHBERG ROBERTSELL

2026-07-07100,000 shares @ $4.96

Kochendoerfer GerdSELL

2026-06-2650,000 shares @ $5

Craig Kevin JamesSELL

2026-06-2542,579 shares @ $4.51

Craig Kevin JamesSELL

2026-04-2042,579 shares @ $5

Craig Kevin JamesSELL

2026-03-20100,000 shares @ $3.55

Recent News

2026-07-07 12:40:00

2026-07-06 16:09:03

2026-07-06 15:59:18

2026-07-06 14:25:30

2026-06-25 10:28:19

Data last updated: Jul 13, 2026, 12:44 PM